Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia

Clofarabine (40 mg/m 2 /day × 5) and high-dose cytosine arabinoside (Ara-C, 1–2 g/m 2 /day × 5) were used in 10 men and 11 women, at a median age of 45 (22–62) years, with refractory ( N  = 4) and relapsed ( N  = 17) acute myeloid leukaemia, after a median of 3 (2–5) prior regimens. Grade 4 myelosup...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2011-11, Vol.90 (11), p.1277-1281
Main Authors: Tse, Eric, Leung, Anskar Y. H., Sim, Joycelyn, Lee, Harold K. K., Liu, Herman S. Y., Yip, Sze-Fai, Kwong, Yok-Lam
Format: Article
Language:English
Subjects:
Adenine Nucleotides - administration & dosage
Adenine Nucleotides - adverse effects
Adult
Antimetabolites, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - adverse effects
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Arabinonucleosides - administration & dosage
Arabinonucleosides - adverse effects
Cytarabine - administration & dosage
Cytarabine - adverse effects
Female
Hematology
Humans
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - prevention & control
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original
Original Article
Recurrence
Remission Induction
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clofarabine (40 mg/m 2 /day × 5) and high-dose cytosine arabinoside (Ara-C, 1–2 g/m 2 /day × 5) were used in 10 men and 11 women, at a median age of 45 (22–62) years, with refractory ( N  = 4) and relapsed ( N  = 17) acute myeloid leukaemia, after a median of 3 (2–5) prior regimens. Grade 4 myelosuppression was observed in all cases, with two patients dying of bacterial sepsis. Nine patients achieved a complete remission. Disease status, number of prior therapies, and cytogenetic aberrations were not associated with the outcome. However, remission was only achieved with Ara-C at 2 g/m 2 /day and not 1 g/m 2 /day (9/15 versus 0/4, P  = 0.03).
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-011-1223-2